Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 139-147 , March 2003

Hormone replacement therapy and endometrial, ovarian and colorectal cancer

  • M Gambacciani, MD (Assistant Professor in Obstetrics and Gynecology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Department of Obstetrics and Gynecology ‘Piero Fioretti’, University of Pisa, Via Roma 67, 56100, Pisa, Italy. Tel.: +39-50-992385; Fax: +39-50-553410.
    • ,
  • P Monteleone, MD (Medical Doctor, Obstetrics and Gynecology)
    • ,
  • A Sacco, MD (Medical Doctor)
    • ,
  • A.R Genazzani, MD, PhD (Professor in Obstetrics and Gynecology)

References 

  1. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. Maturitas. 2001;40:117–130
  2. Kurman RJ, Kaminski PF, Norris HJ. The behaviour of endometrial hyperplasia. A long-term of untreated hyperplasia in 170 patients. Cancer. 1985;56:403–412
  3. Shapiro S, Kelly JP, Rosenberg L, et al.  Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. New England Journal of Medicine. 1985;313:969–972
  4. Cushing KL, Weiss NS, Voigt LF, et al.  Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstetrics & Gynecology. 1998;91:35–39
  5. Shiff I, Sela HK, Cramer D, et al.  Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertility and Sterility. 1982;37:79–82
  6. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. Journal of Clinical Pharmacology. 1995;35 (supplement 9):18S–24S
  7. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proceedings of the Society of Experimental Biology and Medicine. 1998;217:6–16
  8. Granberg S, Eurenius K, Lindgren R, Wilhelmsson L. The effects of oral estriol on the endometrium in post-menopausal women. Maturitas. 2002;42:149–156
  9. Weiderpass E, Baron JA, Adami HO, et al.  Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353:1824–1828
  10. Shapiro S, Kelly JP, Rosenberg L, et al.  Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. New England Journal of Medicine. 1985;313:969–972
  11. Kelly RM, Baker WH. Progesterone for endometrial cancer. New England Journal of Medicine. 1961;246:216–220
  12. Pike MC, Peters RK, Cozen W, et al.  Estrogen–progestin replacement therapy and endometrial cancer. Journal of the National Cancer Institute. 1997;89:1110–1116
  13. The Scandinavian Long Cycle Study Group Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas. 1999;32:161–170
  14. Weiderpass E, Adami H-O, Baron JA, et al.  Risk of endometrial cancer following estrogen replacement with and without progestins. Journal of the National Cancer Institute. 1999;91:1131–1137
  15. Grady D, Gebretsadik T, Kerlikowske K, et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstetrics & Gynecology. 1995;85:304–313
  16. Greendale A, Lee NP, Arriola ER. The menopause. Seminar. Lancet. 1999;353:571–580
  17. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association. 2002;288:321–333
  18. Weiderpass E, Adami HO, Baron JA, et al.  Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10:277–284
  19. Endometrial Cancer Collaborative Group Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstetrics & Gynecology. 1993;81:265–271
  20. Levi F, La Vecchia C, Gulie C, et al.  Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. European Journal of Cancer. 1993;29A:1445–1449
  21. von Dadelszen P, Gillmer MDG, Gray MD, et al.  Endometrial hyperplasia and adenocarcinoma during tibolone (Livial) therapy. British Medical Journal. 1994;101:158–161
  22. Cummings SR, Eckert S, Krueger KA, et al.  The effect of raloxifene on risk of breast cancer in post-menopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. Journal of the American Medical Association. 1999;281:2189–2197
  23. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstetrics & Gynecology. 1986;67:326–330
  24. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecological Oncology. 1990;36:189–191
  25. Chapman JA, DiSaia PJ, Osann K, et al.  Estrogen replacement in surgical stage I and II endometrial cancer survivors. American Journal of Obstetrics and Gynecology. 1996;175:1195–1200
  26. Surriano KA, McHale M, McLaren CE, et al.  Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obsterics & Gynecology. 2001;97:555–560
  27. Slattery ML, Edwards SL, Boucher KM, et al.  Lifestyle and colon cancer: an assessment of factors associated with risk. American Journal of Epidemiology. 1999;150:869–877
  28. Slattery ML, Edwards SL, Anderson K, Caan BJ. Vitamin E and colon cancer: is there an association?. Nutrition and Cancer. 1998;30:2016
  29. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al.  Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the nutritional prevention of cancer trial. Cancer Epidemiology Biomarkers & Prevention. 2002;11:630–639
  30. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor subtypes and ER beta isoforms in colon cancer. Cancer Research. 2001;61:632–640
  31. Issa JP, Ottaviano YL, Celano P, et al.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genetics. 1994;7:536–540
  32. Slattery ML, Patter JD, Curtin K, et al.  Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Research. 2001;61:126–130
  33. Smirnoff P, Liel Y, Gnainsky J, et al.  The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncology Research. 1999;11:255–264
  34. Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history, and colon cancer (Seattle, Washington, USA). Cancer Causes Control. 1994;5:359–366
  35. La Vecchia C, Franceschi S. Reproductive factors and colorectal cancer. Cancer Causes Control. 1991;2:193–200
  36. Martinez ME, Grodstein F, Giovannucci E, et al.  A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiology Biomarkers & Prevention. 1997;6:1–5
  37. Talamini R, Franceschi S, Dal Maso L, et al.  The influence of reproductive and hormonal factors on the risk of colon and rectal cancer in women. European Journal of Cancer. 1998;34:1070–1076
  38. Negri E, La Vecchia C, Parazzini F, et al.  Reproductive and menstrual factors and risk of colorectal cancer. Cancer Research. 1989;49:7158–7161
  39. Fernandez E, Franceschi S, La Vecchia C. Colorectal cancer and hormone replacement therapy: a review of epidemiological studies. Journal of the British Menopause Society. 2000;6:8–14
  40. Newcomb PA, Storer BE. Post-menopausal hormone use and risk of large-bowel cancer. Journal of the National Cancer Institute. 1995;87:1067–1071
  41. Hébert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiology Biomarkers & Prevention. 1998;7:553–559
  42. Fernandez E, La Vecchia C, Braga C, et al.  Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiology Biomarkers & Prevention. 1998;7:329–333
  43. Grodstein F, Martinez E, Platz EA, et al.  Post-menopausal hormone use and risk for colorectal cancer and adenoma. Annals of Internal Medicine. 1998;128:705–712
  44. Grodstein F, Newcomb PA, Stampfer MJ. Post-menopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. American Medical Journal. 1999;106:574–582
  45. Slattery ML, Anderson K, Samowitz W, et al.  Hormone replacement therapy and improved survival among post-menopausal women diagnosed with colon cancer (USA). Cancer Causes Control. 1999;10:467–473
  46. La Vecchia C. Epidemiology of ovarian cancer: a summary review. European Journal of Cancer Prevention. 2001;10:125–129
  47. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. American Journal of Epidemiology. 1992;136:1184–1203
  48. Negri E, Tzonou A, Beral V, et al.  Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. International Journal of Cancer. 1999;80:848–851
  49. Rodriguez C, Patel AV, Calle EE, et al.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Journal of the American Medical Association. 2001;285:1460–1465
  50. Lacey JV, Mink PJ, Lubin JH, et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. Journal of the American Medical Association. 2002;288:334–341
  51. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. British Journal of Obstetrics and Gynaecology. 1990;97:1080–1086
  52. Steinberg KK, Thacker SB, Smith SJ, et al.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. Journal of the American Medical Association. 1991;265:1985–1990

PII: S1521-690X(02)00086-6

doi: 10.1016/S1521-690X(02)00086-6

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 139-147 , March 2003

Article Tools